mfn-arc-event-report

Interim Report Q2 2026 Nanologica AB (publ)

31 August, 2026

FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 24,297 thousand (2,327) and for the half-year to SEK 45,753 thousand (13,079). Operating profit for the quarter amounted to SEK -18,073 thousand (-11,280) and for the half-year to SEK 48,999 thousand (-20,521). Operating profit for the first half of the year is affected by the acquisition of Syntagon being recorded as an operating income of SEK 75,676 thousand. Profit before tax for the quarter

Delårsrapport Q2 2026 Nanologica AB (publ)

31 August, 2026

FINANSIELL SAMMANFATTNING Nettoomsättningen för andra kvartalet uppgick till 24 297 TSEK (2 327) och för halvåret till 45 753 TSEK (13 079). Rörelseresultatet för kvartalet uppgick till -18 073 TSEK (-11 280) och för halvåret till 48 999 TSEK (-20 521). Rörelseresultatet för halvåret påverkas av att förvärvet av Syntagon bokförts som en rörelseintäkt om 75 676 TSEK. Resultatet före skatt för kvartalet uppgick till -18 696 TSEK (-12 829) och för halvåret till 47 079

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.